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Background. The citation rate for articles is viewed as a measure of their importance and impact; however, little is known
about what features of articles are associated with higher citation rate. Methodology/Principal Findings. We conducted
a cohort study of all original articles, regardless of study methodology, published in the Lancet, JAMA, and New England
Journal of Medicine, from October 1, 1999 to March 31, 2000. We identified 328 articles. Two blinded, independent reviewers
extracted, in duplicate, nine variables from each article, which were analyzed in both univariable and multivariable linear least-
squares regression models for their association with the annual rate of citations received by the article since publication. A
two-way interaction between industry funding and an industry-favoring result was tested and found to be significant
(p=0.02). In our adjusted analysis, the presence of industry funding and an industry-favoring result was associated with an
increase in annual citation rate of 25.7 (95% confidence interval, 8.5 to 42.8) compared to the absence of both industry funding
and industry-favoring results. Higher annual rates of citation were also associated with articles dealing with cardiovascular
medicine (13.3 more; 95% confidence interval, 3.9 to 22.3) and oncology (12.6 more; 95% confidence interval, 1.2 to 24.0),
articles with group authorship (11.1 more; 95% confidence interval, 2.7 to 19.5), larger sample size and journal of publication.
Conclusions/Significance. Large trials, with group authorship, industry-funded, with industry-favoring results, in oncology
or cardiology were associated with greater subsequent citations.
Citation: Kulkarni AV, Busse JW, Shams I (2007) Characteristics Associated with Citation Rate of the Medical Literature. PLoS ONE 2(5): e403.
doi:10.1371/journal.pone.0000403
INTRODUCTION
The dissemination of important research findings through the
medical community begins with publication in peer-reviewed
journals, but is continued through citation of the original work in
subsequent publications. The number of citations received by an
article is viewed as a marker for the importance of the original
research and is reflected in the impact factor of journals in which
the original paper was published. The impact factor is calculated
as the mean number of citations received in a year for all articles
published in the journal in the previous 2 years [1].
Although reference bias in the medical literature has been well
established, the tendency to over-represent studies with positive
findings [2–5], limited work has been done to determine what
variables affect the number of citations an original paper will
receive [6–8]. We therefore undertook a study to determine what
factors were associated with an increased rate of citation using
a cohort of articles published in leading medical journals. In
particular, we examined whether certain variables that have been
empirically linked to study quality or bias had a positive or
negative impact on subsequent citation rate.
METHODS
Selection of Journals and Articles
Our cohort of articles assembled included all original research
papers published in the 6 month period between October 1, 1999
and March 31, 2000 appearing in the three general medical
journals with the highest impact factors according to the Institute
of Scientific Information’s Journal Citation Report (ISI-JCR): the
New England Journal of Medicine (NEJM), the Journal of the American
Medical Association (JAMA), and the Lancet. We included all articles
under the following table of content headings, regardless of study
methodology: ‘‘Original Articles’’ in NEJM, ‘‘Original Contribu-
tions’’ in JAMA, and ‘‘Original Research–Articles’’ in Lancet.W e
excluded all other articles, including editorials, review articles,
special articles, case reports, and research letters.
Data Extraction
Two reviewers (AVK and JWB) trained in health research
methodology extracted data independently and in duplicate, for
the following variables: 1) the journal in which the article appeared
(NEJM, JAMA,o rLancet) and the month of publication; 2) study
design (randomized trial, prospective observational study, retro-
spective study, survey study, or meta-analysis); 3) clinical category
of the article, defined as the medical subspecialty to which the
main conclusion of the article was most applicable: anesthesiology,
cardiovascular, dermatology, endocrinology, gastroenterology,
general medicine, infectious disease, musculoskeletal, nephrology,
neurology, obstetrics/gynecology, oncology, ophthalmology, pe-
diatrics, psychiatry, or respirology; 4) whether the author by-line
for the article included group authorship; 5) country in which the
research was performed (defined as the country or countries in
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did not use research participants, e.g., meta-analyses, the country
of the corresponding author); 6) sample size of the study (in cases
of meta-analysis, the sample size was taken as the total number of
patients in all analyzed studies); 7) if an industry-affiliated drug or
device was under investigation and whether the results favored the
intervention or not; 8) declared industry funding; and 9) if the
study had been reported in the lay media. Reviewers resolved
discrepancies by discussion.
Industry was defined as for-profit companies and excluded all
government agencies and non-profit private agencies. Industry
funding was considered present if there was any acknowledgement
of direct industry support for the research study (including direct
funding of the study or supplying of drugs or medical devices).
This did not include author-declared conflicts arising from having
received individual consultant fees, for example.
In cases where studies explored the efficacy of an industry-
affiliated device or drug two reviewers (AVK and JWB) in-
dependently evaluated whether the results would be considered
favorable to industry. There is no standardized definition of positive
results [9], and we considered study results favorable to industry if
study findings suggested beneficial health effects or absence of
expected adverse health effects with regards to the intervention
under study. Disagreement was resolved through discussion. To
explore the reliability of assessing industry-favouring status prior to
data extraction, the same two reviewers independently evaluated 20
randomly selected studies from our cohort using a computer-based
random number generator and found very good inter-observer
reliability (kappa=0.80).
To inform public interest in each study we searched the
Associated Press health news wire during the 6-month period
following publication of each article to determine if the study had
been reported by the lay media. All data were extracted prior to
determination of our primary outcome measure-the number of
citations received.
Outcome Measure Assessment
The primary outcome measure (annual rate of citation) was
defined as the number of citations received per year since
publication. Approximately five years (ranging from 57 months to
63 months) after we assembled our cohort, we conducted a citation
search using the Institute of Scientific Information’s (ISI) electronic
version of Science Citation Index (http://isiknowledge.com) for each
article, using a cited reference search, to determine the number of
times the article had subsequently been cited in the medical
literature. All citation searches were carried out in a single one
week period in December 2004. A citation is counted by ISI if an
article appears in a reference list in any of the approximately 8700
journals indexed by ISI. This would include reference lists
associated with scientific papers, editorials, letters, or general
interest articles. The initial query was performed by two of us
independently (AVK and JWB) using the first author’s name or
group authorship name, journal title, and year of publication. If
this query failed to yield any citations for an article, we conducted
a search for the study title to limit misclassification of an article as
having zero subsequent citations.
Statistical Analysis
We performed all analyses using SPSS 13.0 statistical software
(SPSS Inc., Chicago, IL). Amongst the 16 subgroups within the
clinical category variable, only those with at least 20 articles each
were retained as distinct subgroups for analysis; all other
subgroups were combined into ‘‘others’’. The country in which
the research was performed was analyzed as either exclusively/
partially in the United States or exclusively outside of the United
States. Because of the highly skewed distribution of sample size
(mean of 53310, but ranging from 1 to 3.3 million) we used a log10-
transformation for this analysis. As funding source and study
conclusions have been shown to be associated [10], so-called
‘‘sponsorship bias’’ [11], we decided, a priori, to test declared
industry funding and industry-favoring results for interaction. We
calculated the median and mean (with associated standard
deviation [SD] or 95% CI) annual citation rate for all articles.
We used linear least-squares regression with the annual rate of
citation as the dependent variable to explore associations. Each of
the independent variables was initially tested in a univariable
regression model. The F-test was used to calculate the level of
significance and we included variables in our multivariable model if
theirlevelofsignificancewasp,0.10ortheysubstantiallyaltered the
significance of another variable in the model. We used a step-
forward method for entry into our multivariable analysis, in order
from lowest p-value to highest. A variable was considered statistically
significant if it had a p-value,0.05 in the final multivariable model.
Multicollinearity was deemed concerning if the variance inflation
factor for any independent variable was greater than 5 [12].
RESULTS
Our literature search generated 328 articles that were grouped
into the following clinical categories: infectious disease (n=62),
cardiovascular (n=57), oncology (n=30), general medicine
(n=29), and obstetrics/gynecology (n=25), leaving 125 articles
assigned to ‘‘other’’. Ninety-two (28.0%) studies were randomized
and 68 (20.7%) were group authored (either exclusively or in
addition to named individual authors). The majority of studies
were performed either partly or exclusively in the United States
(54.0%, 177 of 328). Eighty-two articles (25.0%) declared industry
funding, of which approximately half (n=42) reported industry-
favoring results. Thirty-four studies reported industry-favoring
results, but were not industry-funded. Ninety-seven articles
(29.6%) had been reported by the Associated Press. (Table 1)
Our 328 eligible articles were cited a total of 38,381 times and
the annual rate of citation ranged from 1.0 to 392.9 (median 14.1;
mean 23.8, SD=31.6).
Univariable regression models using annual rate of citation as the
dependent variable yielded p-values,0.10 for all independent
variables, except month of publication (p=0.50).(Table 1) The
variance inflation factors of all independent variables were less than
2.1, suggesting that multicollinearity was not a concern. Graphical
examination of residuals against predicted values did not suggest
a violation of the linearity assumption for the independent variables.
The following variables were retained in our multivariable
regression model: industry funding, industry-favoring result,
clinical category of article, group authorship, journal of publica-
tion, and sample size. (Table 1)
Based on our a priori hypothesis, a two-way interaction between
industry funding and industry-favoring result was tested and found
to be significant (p=0.02). Therefore, if a study was industry
funded, an industry-favoring result was associated with a signifi-
cantly higher annual citation rate (an increase of 21.7; 95%
CI=9.2 to 34.3). However, if a study was not industry funded,
a favorable result was not associated with a significant difference in
annual citation rate (an increase of 2.5; 95% CI=28.2 to 13.2).
The unstandardized regression coefficients presented in Table 1
represent the difference in the annual citation rate between the
subgroup and the reference category. Our model explained
approximately 20% of the variance (adjusted R
2=0.20) in annual
citation rates of our cohort.
Predictors of Citation
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..................................................................................................................................................
Variable
Number of
articles
Univariable Analysis
(unstandardized regression
coefficients (95% CI)) p-value
Multivariable Analysis
(unstandardized regression
coefficients (95% CI)) p-value
Industry funding ,0.001 0.002
-no 246 reference category See interaction term *
-yes 82 19.9 (12.2 to 27.5)
Industry favoring result ,0.001 0.004
-no 252 reference category See interaction term *
-yes 76 19.4 (11.6 to 27.3)
Industry funding & Industry favoring result
(interaction term) *
n/a
{ 0.02
-no industry funding and no industry favoring result 212 n/a
{ reference category
-industry funding, but no industry favoring result 40 n/a
{ 3.9 (26.1 to 14.0)
-no industry funding, but industry favoring result 34 n/a
{ 2.5 (28.2 to 13.2)
-industry funding and industry favoring result 42 n/a
{ 25.7 (8.5 to 42.9)
Clinical category 0.001 0.004
-other 125 reference category reference category
-cardiovascular 57 17.8 (8.1 to 27.5) 13.31 (3.9to 22.3)
-general medicine 29 8.4 (24.1 to 20.9) 9.1 (23.2 to 21.5)
-oncology 30 13.5 (1.2 to 25.8) 12.6 (1.2 to 24.0)
-infectious disease 62 20.7 (210.1 to 8.7) 22.9 (211.7 to 5.8)
-obstetrics & gynaecology 25 27.7 (221.0 to 5.6) 26.5 (219.0 to 5.9)
Group authorship ,0.001 0.01
-no 260 reference category reference category
-yes 68 20.3 (12.2 to 28.5) 11.1 (2.7 to 19.5)
Journal of publication ,0.001 0.002
-NEJM 102 reference category reference category
-JAMA 100 28.6 (217.2 to 0.0) 29.7 (218.0 to 21.5)
-Lancet 126 216.3 (224.4 to 28.2) 213.1 (220.1 to 25.6)
Sample size (log10 transformed) 3.1 (0.2 to 6.0) 0.04 2.8 (0.1 to 5.7) 0.04
News media coverage of article ,0.001 n/a
{
-no 231 reference category n/a
{
-yes 97 13.5 (6.1 to 20.9) n/a
{
Location of study 0.001 n/a
{
-not in United States 151 reference category n/a
{
-partly/exclusive in United States 177 11.9 (5.2 to 18.7) n/a
{
Study design 0.01 n/a
{
-randomized 92 13.4 (22.1 to 28.8) n/a
{
-prospective 108 1.2 (214.1 to 16.4) n/a
{
-retrospective 92 22.4 (217.8 to 13.0) n/a
{
-meta-analysis 15 2.8 (218.4 to 23.9) n/a
{
-survey 19 reference category n/a
{
Month of publication (from 1=October 1999 to
6=March 2000)
0.7 (21.3 to 2.7) 0.50 n/a
{
95% CI=95% confidence interval
{n/a=not applicable (variable was not included in the model)
*Since a significant interaction term between these two variables was included in the final multivariable model, their effects are dependent on each other and are
presented together.
doi:10.1371/journal.pone.0000403.t001
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Findings
Our analysis of a consecutive cohort of 328 original articles pub-
lished in leading general medical journals found that declared
industry funding with industry-favoring results, articles reporting
data related to oncology or cardiovascular medicine, group
authorship, higher impact journal of publication, and larger
sample size were associated with higher rates of subsequent annual
citation. Studies that declared industry funding and reported
industry-favoring results were associated with the largest increase
in annual citation rate.
Limitations and Strengths
Our review has potential limitations. Despite our aggressive search
strategy it is possible that some citations were missed, and the
difficulty in accurately retrieving citations of group-authored
articles, in particular, has been documented [13,14]. However, this
islikelytobeonlyarelativelysmallproportion(only10articlesinour
sample were exclusively group-authored) which would be unlikely to
substantially alter our main results. Further, we found group
authorship was associated with greater citations which provides
additional assurance that our search strategy was successful.
We did not assess self-citation, which has been associated with
increased frequency of subsequent citation [15,16]. As well, we
assumed all subsequent citations to be quantitatively equal and we
did not assess the context in which the citation appeared. For
example, there may be differences between studies that are cited in
a positive fashion versus those that are cited in a critical or negative
fashion.
Despite including many potentially relevant independent
variables, our final model only accounted for a moderate amount
of the variability in the citations received (adjusted R
2=0.20). Our
model, however, was able to provide more explanation of the
variance in citation frequency than the previous model by
Callaham et al. (pseudo-R
2=0.14) [6] and this is likely due to our
inclusion of declared industry funding and industry-favoring
results as variables. In fact, when these variables are removed
from our model, the adjusted R
2 falls to 0.15.
Our multivariable analysis highlights some of the limitations in
the interpretation of the impact factor. For example, using our
data, the difference in the annual citation rate between articles
appearing in the highest and lowest impact journals in our sample
(NEJM and Lancet) was 16.3, roughly in keeping with the 15.8
difference in their 2001 impact factors (29.1 and 13.3, re-
spectively). However, the adjusted difference in annual citation
rate was approximately 10.0 (95% CI=1.7 to 18.3) (see Table 1),
highlighting the fact the impact factor is attributable to more than
just the journal of publication.
Our work has additional strengths. Our cohort of 328 articles is
the result of a systematic search. Our data collection was
comprehensive and careful, including independent judgment and
abstraction of data at all stages conducted by methodological
trained reviewers, and use of targeted, relevant analyses. Our
results are not, however, generalizable to articles published in
periodicals aside from the 3 high-impact general medical journals
we reviewed.
Implications
The rate of citation is used to calculate journal impact factors,
which are viewed as a sign of journal importance and prestige.
Subsequent citation and journal impact factor are commonly used
as criteria for academic promotions within universities and the
works of more accomplished researchers, including Nobel
laureates, receive more citations than the works of other
researchers [17]. Citation of articles is also an essential component
of the dialogue of medical research–a dialogue which occurs
largely within the pages of peer-reviewed journals. By re-iterating
published research, citation serves to further the influence of their
results.
In a review of emergency medicine papers, Callaham et al.
found that the impact factor of the publishing journal was
associated with the largest increase in citation rates [6]. Their
study included a broader range of journal impact factors (ranging
from 0.23 to 24.5) than our study, which was limited to only three
very high impact factor journals (ranging from 13.3 to 29.1 in
2001). In our analysis, there was an association between journal
and citation rate and this was in the expected direction, with articles
in the higher impact journals having a higher rate of citation.
The impact factor of a journal has empirically been shown to be
associated with article quality in some studies [18] but not in
others [6]. In our adjusted analysis, larger sample size was
associated with a higher citation rate while the design of the study
was not. Some authors have described an association between
citations and newsworthiness [6,7]; however, the presence of an
Associated Press news story (an indicator of newsworthiness and
general public interest) did not demonstrate a significant enough
association with citation rate to be included in our final multivari-
able model (5.5 more citations per year (95% CI=22.2 to 13.2,
p=0.20) when added to the existing multivariable model).
The incidence of group authorship in the medical literature has
steadily increased over the last two decades [19]. In our analysis,
group-authored articles received approximately 11.1 more cita-
tions per year than articles with only individually named authors,
a result consistent with previous findings by Dickersin et al. [13].
One could hypothesize that papers with group authorship are
potentially larger studies, of higher methodological rigor, and of
possible greater general interest. However, our multivariable
analysis attempted to correct for such confounding variables. We
did not study the effect of self-citation, which may account for up
to 20% of subsequent citations [15]. It can be hypothesized that
with group authorship (and, therefore, a greater number of
authors) the potential impact of self-citation may be greater,
thereby at least partly accounting for the higher citation rate.
The potential bias associated with industry-sponsored research
has been suggested in previous works that have found an
association between industry funding and the reporting of
favorable results [20–22] and lower methodological quality [18].
Friedberg et al. found that pharmaceutical company sponsorship
of economic analyses was associated with reduced likelihood of
reporting unfavorable results [23]. Djulbegovic et al. reported that
industry-funded trials more often compared innovative treatments
to either a placebo arm or no therapy, resulting in a higher
proportion of such studies favoring the new intervention [24]. This
type of research has generally concentrated on examining the
association between industry funding and study results. However,
the next step in the dissemination of results is through their
subsequent citation, and Patsopoulos et al. have recently shown
that the proportion of most frequently cited articles funded by
industry has been increasing [25].
After controlling for a number of other independent variables
our analysis found that studies with declared industry funding
received approximately 22 more citations per year only if their
results were industry-favoring. The influence of 22 additional
citations per year certainly appears to be substantial when put in
context to the impact factors of the most cited journals in general
medicine (which range from 10.4 to 44.0 for the top five journals
in 2005). Therefore, the added influence appears to be the
Predictors of Citation
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impact journal. These extra citations may have the effect of
amplifying the results of these studies in the medical literature.
Conclusions
In our analysis, large trials, with group authorship, industry-
funded, with industry-favoring results, in oncology or cardiology
were associated with greater subsequent citations. Declared
industry funding with industry-favoring results was associated
with the largest increase in annual citation rate. The medical
community should be aware of the potential for these studies and
their results to have greater impact in the subsequent medical
literature.
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